Sugi Predict

Sugi Predict / Targets / SPTBN1

SPTBN1

Spectrin beta chain, non-erythrocytic 1 · Q01082 · SPTBN1 on Sugi Atlas →

0 patent compounds predicted against SPTBN1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SPTBN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia PHASE2/PHASE3COMPLETED
Hereditary Sensory Neuropathy Serine Trial PHASE2UNKNOWN
Hemolysis in Patients With Hereditary Spherocytosis (HS) nanUNKNOWN
A Novel Mutation of the Spectrin Gene nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Congenital Hemolytic and Dyserythropoietic Anemias nanRECRUITING
Mechanisms of Cell Death in Spinal Muscular Atrophy nanCOMPLETED
Screening for Alpha Thalassemia in Healthy Volunteers nanACTIVE_NOT_RECRUITING
Red Cell Distribution Width Index Versus Red Cell Distribution Width as Discriminating Guide for Iron Deficiency Anaemia and Beta Thalassemia Trait . nanUNKNOWN
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker) nanCOMPLETED
Classification of Cerebral Palsy Subtypes nanCOMPLETED
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations nanUNKNOWN
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders nanRECRUITING
Evaluation of Brain Dysfunction in Patients with Duchene Muscular Dystrophy nanNOT_YET_RECRUITING
Study of Constitutional Platelet Disease nanUNKNOWN
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy nanWITHDRAWN
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases nanRECRUITING
The Nosology and Etiology of Leukodystrophies of Unknown Causes nanCOMPLETED
Longitudinal Study of Neurogenetic Disorders nanRECRUITING
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome nanRECRUITING
The Myelin Disorders Biorepository Project nanRECRUITING
Shwachman Diamond Syndrome Registry and Study nanRECRUITING
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
The Role of Erythropoietin in Myelodysplastic Syndrome nanCOMPLETED
The Etiology and Progression of Brain Tumors nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SPTBN1 binder may also engage these)

ProteinNameSimilarity
Q62261 — 1.000 Q62261 →
Q00963 — 0.998 Q00963 →
P15508 — 0.992 P15508 →
P11277 — 0.990 P11277 →
Q08043 — 0.990 Q08043 →
Q9JI91 — 0.988 Q9JI91 →
Q3ZC55 — 0.987 Q3ZC55 →
O88990 — 0.987 O88990 →
O15020 — 0.987 O15020 →
P35609 — 0.987 P35609 →
Q9QWN8 — 0.987 Q9QWN8 →
P18091 — 0.987 P18091 →
Q90734 — 0.987 Q90734 →
Q7PKQ5 — 0.987 Q7PKQ5 →
P13395 — 0.986 P13395 →
Q5RCS6 — 0.986 Q5RCS6 →
P57780 — 0.986 P57780 →
P07751 — 0.986 P07751 →
A5D7D1 — 0.985 A5D7D1 →
ACTN4 Alpha-actinin-4 0.984 landscape →
Q2PFV7 — 0.984 Q2PFV7 →
SPTAN1 Spectrin alpha chain, non-erythrocytic 1 0.984 landscape →
Q9QXQ0 — 0.983 Q9QXQ0 →
L7UZ85 — 0.983 L7UZ85 →
P20111 — 0.983 P20111 →
Q3B7N2 — 0.983 Q3B7N2 →
ACTN1 Alpha-actinin-1 0.982 landscape →
P02549 — 0.982 P02549 →
Q7TPR4 — 0.981 Q7TPR4 →
Q9Z1P2 — 0.981 Q9Z1P2 →